A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal...(nual human influenza mortality rates. It...)

Beyond prediction, this new replikin-based technology also can be applied to combat influenza -- and to develop new vaccines that are more accurate and effective than current technology provides. Replikins have successfully demonstrated this capability when used against a virus in shrimp, which are susceptible to several devastating viral diseases. The replikin-based vaccine developed by Replikins to combat Taura Syndrome virus had a stunning result on the test population, protecting 91% of the shrimp against this deadly virus. Replikin vaccines work orally -- and can be synthesized far more quickly than conventional viral vaccines. The vaccine used to save the shrimp was manufactured in seven days. You can imagine what this type of rapid lead time would allow for making on-demand strain-specific influenza vaccines, which with traditional methods must be prepared nine months up to a year in advance.

Replikins is working to expand the capabilities of this vaccine technology and looks forward to making significant inroads to control H5N1 and other influenza populations.

Replikins are the viral tool of the future -- making accurate predictions in humans and animals now, through the FluForecast(R) service, and hopefully becoming a front-line weapon to stop viral pandemics in the future.

Contact: John McKenney, Replikins Ltd., 617-536-0220. An expanded version of this press release, with charts and additional data, will be posted on Replikins' website -- http://www.Replikins.com -- on November 13th.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.